Current approaches to improve ESCC outcomes focus on addressing key mutations and pathways involved in ESCC, for example, programmed death receptor 1/programmed cell death‐ligand 1 (PD‐1/PD‐L1) and epidermal growth factor receptor (EGFR) signaling.36, 39. This evidence concerns the gene CD274 and esophageal squamous cell carcinoma.